Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, reported its financial results for the first quarter of 2025. The company recorded a net loss of $2.6 million, compared to a net loss of $1.6 million in the same period in 2024. Cash, cash equivalents, and investments as of March 31, 2025, totaled $54.6 million. Monopar anticipates that these funds will sustain operations through December 31, 2026. Research and development (R&D) expenses rose to $1.643 million for the first quarter of 2025, an increase from $966,000 in the first quarter of 2024. This increase is primarily due to a $611,000 rise in R&D personnel expenses, including stock-based compensation, and a $69,000 increase in clinical trial site activities related to MNPR-101 for radiopharmaceutical use. General and administrative (G&A) expenses also increased to $1.578 million in the first quarter of 2025, from $757,000 in the corresponding quarter of 2024. The rise in G&A expenses is mainly attributed to a $416,000 increase in Board compensation due to the grant of stock options during the quarter. In terms of business developments, Monopar presented long-term efficacy and safety data for ALXN1840 at the EASL International Liver Congress 2025. The data supports ALXN1840 as a potential treatment for Wilson disease. The company is preparing to submit a New Drug Application (NDA) to the FDA in early 2026. Additionally, Monopar is advancing its MNPR-101 related clinical trials in Australia and continues its preclinical work with MNPR-101-Ac.